ARGENTA
16.9.2021 11:12:12 CEST | Business Wire | Press release
Argenta, the only combined global contract research organization (CRO) and contract development & manufacturing organization (CDMO) dedicated to animal health, announced today that it has acquired Klifovet, the leading CRO and Regulatory Affairs consultancy organization in Europe. Financial details of the transaction were not disclosed. Klifovet founder and CEO Dr. Klaus Hellmann will continue to lead Klifovet and will join Argenta’s senior leadership team.
Founded in 1997 by Dr. Klaus Hellmann and located in Munich, Germany, Klifovet has built a leading reputation in the animal health industry, providing extensive expertise in clinical research and regulatory affairs. Its ~50 employees have had successful involvement in hundreds of studies, and their expertise and knowledge has been critical to numerous marketing authorizations for pharmaceutical, biological, immunological, and novel therapies. Its client base comprises the world’s top animal health and nutrition companies as well as many promising startups.
“The acquisition of Klifovet, and the expansion into the EU, is part of Argenta’s growth strategy and provides our customers the opportunity for a seamless, global Molecule to Market product development experience,” said Ben Russell, CEO of Argenta. “Importantly, Argenta and Klifovet share strategic and cultural values built around customer excellence, teamwork, partnership, and innovation. I am very pleased to welcome Klifovet as a valued member of the Argenta Group and collectively work to continue to advance animal health to the benefit of our clients.”
The combined business will be a global, full-value strategic partner, stimulating innovation and supporting large and small animal health and nutrition companies. Klifovet will particularly complement Argenta's Clinical & Regulatory Services team based in the United States, offering an unparalleled level of expertise, and access to the largest transatlantic CRO capability in animal health.
“Joining forces with the Argenta Group is 100% in line with Klifovet’s vision of becoming the leading international full-service provider for the development and maintenance of products for animal health, nutrition and wellbeing. The two leading CROs, with a presence in the EU and US, combined with the know-how and capabilities in manufacturing, regulatory services, project management, and product development, create the world’s leading animal health CDMO and CRO. It provides unique and excellent opportunities for both our clients and employees. I am truly convinced this to be a perfect fit and look forward to a great future within the Argenta Group,” said Klaus Hellmann, CEO of Klifovet.
Argenta was advised on the transaction by Stonehaven Consulting AG, a global consulting firm focused on animal health.
About Argenta
Founded in 2006 in New Zealand, Argenta’s talented, diverse and committed employees work on a daily basis to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, Argenta holds a unique position as the only combined global contract research organization (CRO) and contract development & manufacturing organization (CDMO) dedicated to animal health. Argenta operates from “Molecule to Market” in partnership with customers of all sizes from all corners of the world, supporting their Research & Development, clinical research, regulatory, scale up and manufacturing needs along their veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com
About Klifovet
Klifovet AG, based in Munich, Germany, was founded in 1997 and is a full-service Contract Research and Development Organization (CRO), offering regulatory affairs, pre-clinical and clinical studies, GMP compliant manufacturing including clinical supplies, quality assurance, data management and statistical analyses for the animal health and nutrition industry. Where relevant, the organization assures that services comply with VICH GCP, GLP, GCP, GMP, GPhVP and ISO 9001 requirements. Klifovet supports its clients in all aspects of the development and maintenance of products for the animal health and nutrition market. For more information about Klifovet, please visit www.klifovet.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005309/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 22:08:00 CET | Press release
Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl
Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 22:05:00 CET | Press release
Key Takeaways: Enables enterprises to replace high-cost and recurring SaaS licensing fees with high-performance and cost-efficient NVIDIA-based solutions Offerings are derived from Grid Dynamics’ proven customer solutions and leverage NVIDIA’s technology stack Commercially deployed, with additional customers expressing interest NVIDIA and Grid Dynamics jointly presented these solutions at the National Retail Federation (NRF) conference in January 2026 Learn more in NVIDIA’s published blog Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven suc
Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 22:01:00 CET | Press release
Fourth Quarter and Full Year 2025 Financial Highlights Include:Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior yearAdjusted Calculated Billings, full year 2025, up 4.2% from the prior yearAdjusted Annualized Recurring Revenue (ARR) up 3.1% from the prior year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 18:25:00 CET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 18:00:00 CET | Press release
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeksVedolizumab’s safety profile was generally consistent with its known safety profile in adultsResults were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom